Biotech & AI drug discoverySTAT — Biotech

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

According to STAT, AbbVie's experimental therapy lutikizumab, intended for a chronic skin condition, succeeded in a late-stage trial, but the results missed market expectations.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-22T18:22:27+00:00

Published here2026-10-22T19:22:29+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/

Original headline

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.